Regencell Bioscience (NASDAQ:RGC) Shares Up 5.6% – Here’s Why

Shares of Regencell Bioscience Holdings Limited (NASDAQ:RGC – Get Free Report) traded up 5.6% during trading on Wednesday. The company traded as high as $4.76 and last traded at $4.8050. Approximately 19,580 shares traded hands during mid-day trading, a decline of 93% from the average session volume of 288,219 shares. The stock had previously closed at $4.55.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Regencell Bioscience in a research note on Monday, September 21st. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat.com, the stock has a consensus rating of “Sell”.

Read Our Latest Analysis on RGC

Regencell Bioscience Price Performance

The company has a 50 day moving average price of $6.66 and a 200 day moving average price of $15.52.

Regencell Bioscience (NASDAQ:RGC – Get Free Report) last posted its earnings results on Wednesday, October 7th. The company reported ($0.01) EPS for the quarter.

Institutional Investors Weigh In On Regencell Bioscience

A hedge fund recently raised its stake in Regencell Bioscience stock. Bank of America Corp DE raised its position in shares of Regencell Bioscience Holdings Limited (NASDAQ:RGC – Free Report) by 59,113.8% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,172 shares of the company’s stock after buying an additional 17,143 shares during the quarter. Bank of America Corp DE’s holdings in Regencell Bioscience were worth $437,000 as of its most recent SEC filing. 0.13% of the stock is currently owned by institutional investors.

About Regencell Bioscience

(Get Free Report)

Regencell Bioscience Holdings Limited is a Hong Kong-based, clinical-stage bioscience company focused on researching and developing traditional Chinese medicine (TCM) treatments. Its main area of focus is neurocognitive disorders, including attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The company is developing TCM-based treatment protocols and formulations for these conditions. Its work centers on research and clinical evaluation; Regencell is not a developer of established, widely marketed prescription drugs for these disorders.

Featured Articles

Receive News & Ratings for Regencell Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regencell Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.